Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pramipexole Dihydrochloride

FDA-approved product (tablet, oral), marketed as Mirapex, Mirapex Er, Pramipexole Dihydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Pramipexole Dihydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Parkinson disease
  • Restless legs syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dopamine agonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pramipexole Dihydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pramipexole Dihydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study in Healthy People to Compare Two Different Sifrol® Tablets

    NCT06457204 · start 2024-07-02

    Registered record
    Registry ID
    NCT06457204
    Conditions
    Healthy
    Interventions
    Pramipexole manufactured in Ingelheim; Pramipexole manufactured in Ennigerloh
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-07-02
    Completion
    2024-08-12
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPramipexole manufactured in Ingelheim; Pramipexole manufactured in Ennigerloh
    PhasePhase 1
    Registry statusCompleted

  • Phase III Long-Term Extension Study With Dexpramipexole

    NCT06388889 · start 2024-06-12

    Registered record
    Registry ID
    NCT06388889
    Conditions
    Eosinophilic Asthma
    Interventions
    Dexpramipexole Dihydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2024-06-12
    Completion
    2025-12-08
    Enrolment
    509

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEosinophilic Asthma
    InterventionDexpramipexole Dihydrochloride
    PhasePhase 3
    Registry statusTerminated

  • Pramipexole to Enhance Social Connections

    NCT06269146 · start 2024-05-13

    Registered record
    Registry ID
    NCT06269146
    Conditions
    Anxiety Disorders; Anxiety; Depression; Social Disconnection
    Interventions
    Pramipexole Pill; Placebo Pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2024-05-13
    Completion
    2026-03
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety Disorders; Anxiety; Depression; Social Disconnection
    InterventionPramipexole Pill; Placebo Pill
    PhasePhase 2
    Registry statusUnknown

  • A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)

    NCT05813288 · start 2023-03-27

    Registered record
    Registry ID
    NCT05813288
    Conditions
    Eosinophilic Asthma; Asthma; Eosinophilic; Asthma
    Interventions
    Dexpramipexole Dihydrochloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2023-03-27
    Completion
    2025-12-08
    Enrolment
    654

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEosinophilic Asthma; Asthma; Eosinophilic; Asthma
    InterventionDexpramipexole Dihydrochloride; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Pramipexole for Anhedonic Depression

    NCT05355337 · start 2023-02-08

    Registered record
    Registry ID
    NCT05355337
    Conditions
    Psychiatric Disorders Mood; Anhedonia; Depression
    Interventions
    Pramipexole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-02-08
    Completion
    2025-06-04
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychiatric Disorders Mood; Anhedonia; Depression
    InterventionPramipexole; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

    NCT05763121 · start 2023-01-30

    Registered record
    Registry ID
    NCT05763121
    Conditions
    Eosinophilic Asthma; Asthma; Eosinophilic; Asthma
    Interventions
    Dexpramipexole Dihydrochloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2023-01-30
    Completion
    2025-12-08
    Enrolment
    1,061

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEosinophilic Asthma; Asthma; Eosinophilic; Asthma
    InterventionDexpramipexole Dihydrochloride; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression

    NCT04936126 · start 2021-08-07

    Registered record
    Registry ID
    NCT04936126
    Conditions
    Treatment Resistant Depression
    Interventions
    Quetiapine; Amantadine; Pramipexole
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-08-07
    Completion
    2024-09-07
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment Resistant Depression
    InterventionQuetiapine; Amantadine; Pramipexole
    PhasePhase 4
    Registry statusUnknown

  • Study on Bioequivalence of Pramipexole Dihydrochloride Sustained Release Tablets

    NCT04275492 · start 2020-07-24

    Registered record
    Registry ID
    NCT04275492
    Conditions
    Parkinson's Disease
    Interventions
    Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride); Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2020-07-24
    Completion
    2020-12-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    InterventionPraxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride); Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)
    PhaseNot applicable
    Registry statusTerminated

  • Pramipexole to Target "Anhedonic Depression"

    NCT04121091 · start 2019-10-04

    Registered record
    Registry ID
    NCT04121091
    Conditions
    Depression, Bipolar; Depression, Unipolar; Dysthymia; Anhedonia
    Interventions
    Pramipexole Pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-10-04
    Completion
    2021-03-18
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression, Bipolar; Depression, Unipolar; Dysthymia; Anhedonia
    InterventionPramipexole Pill
    PhasePhase 2
    Registry statusCompleted

  • Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients

    NCT03817554 · start 2019-07-01

    Registered record
    Registry ID
    NCT03817554
    Conditions
    Restless Legs Syndrome
    Interventions
    Pramipexole; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2019-07-01
    Completion
    2020-08-31
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRestless Legs Syndrome
    InterventionPramipexole; placebo
    PhasePhase 4
    Registry statusTerminated

  • Antidepressant Discontinuation in Treatment Resistant Depression

    NCT03786614 · start 2019-06-20

    Registered record
    Registry ID
    NCT03786614
    Conditions
    Treatment Resistant Depression
    Interventions
    Discontinuation of serotonergic antidepressants; Continuation of serotonergic medications
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2019-06-20
    Completion
    2024-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTreatment Resistant Depression
    InterventionDiscontinuation of serotonergic antidepressants; Continuation of serotonergic medications
    PhaseNot applicable
    Registry statusUnknown

  • A Study in Patients With Major Depressive Disorder

    NCT03642964 · start 2018-09-10

    Registered record
    Registry ID
    NCT03642964
    Conditions
    Major Depressive Disorder (MDD)
    Interventions
    CTC-501
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-09-10
    Completion
    2025-12-30
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder (MDD)
    InterventionCTC-501
    PhasePhase 2
    Registry statusUnknown

  • A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

    NCT03329508 · start 2018-01-19

    Registered record
    Registry ID
    NCT03329508
    Conditions
    Parkinson Disease; Early Parkinson's Disease
    Interventions
    P2B001 0.6/0.75 mg; Rasagiline 0.75 mg; Pramipexole 0.6 mg; Marketed Pramipexole ER
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-01-19
    Completion
    2021-10-31
    Enrolment
    544

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease; Early Parkinson's Disease
    InterventionP2B001 0.6/0.75 mg; Rasagiline 0.75 mg; Pramipexole 0.6 mg; Marketed Pramipexole ER
    PhasePhase 3
    Registry statusCompleted

  • Infusion of Apomorphine: Long-term Safety Study

    NCT02339064 · start 2015-02

    Registered record
    Registry ID
    NCT02339064
    Conditions
    Idiopathic Parkinson's Disease
    Interventions
    apomorphine infusion
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2015-02
    Completion
    2025-12
    Enrolment
    99

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Parkinson's Disease
    Interventionapomorphine infusion
    PhasePhase 3
    Registry statusActive not recruiting

  • Butrans for Treatment of Restless Legs Syndrome

    NCT02138357 · start 2014-04

    Registered record
    Registry ID
    NCT02138357
    Conditions
    Restless Legs Syndrome
    Interventions
    buprenorphine transdermal delivery system (BTDS); Placebo for BTDS patch
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2014-04
    Completion
    2016-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRestless Legs Syndrome
    Interventionbuprenorphine transdermal delivery system (BTDS); Placebo for BTDS patch
    PhasePhase 4
    Registry statusWithdrawn